A serious adverse event puts ADVM-022’s future in doubt, and it could hurt other eye disease gene therapy players too.
Merck & Co gives up on MK-7110, and on molnupiravir in hospitalised patients.
Admission of a major data error in previous roxadustat presentations leaves the novel anaemia pill’s future in doubt.
The group discontinues its first-generation antisense Huntington’s projects on disappointing efficacy, leaving its next-gen asset with much to prove.
The company placed part of the blame for its mid-stage hearing loss failure on subjects exaggerating their level of hearing loss.
The failure of Roche and Ionis’s late-stage candidate tominersen casts doubt on Wave’s approach, too.
The company’s lead cystic fibrosis asset fails, shifting the focus to the Sanofi-partnered Covid-19 vaccine.